Zbtb7

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Zbtb7, originally named Pokemon, is a gene that may act as a master switch for cancer, and is responsible for the proliferation of cancer throughout surrounding cells. The leader of the research team which discovered this, geneticist Pier Paolo Pandolfi from the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, said the gene is unique in that it is needed for other oncogenes to cause cancer.[1] Discovery of the gene was first published in the January 2005 issue of Nature.[2]

The original name, Pokemon, stands for "POK erythroid myeloid ontogenic factor" and is most likely a backronym of the Pokémon media franchise. The Pokémon Company, not wanting the bad press inherent with its trademark sharing a name with a cancer-causing gene, threatened the center with legal action in December 2005, at which point MSKCC decided to rename it as Zbtb7.[3]

Zbtb7 are the member of the ZBTB protein family that contains zinc finger and BTB domain.[4] It is also known as LRF10 (leukemia/lymphoma-related factor), OCZF11 (osteoclast-derived zinc finger),[5] and FBI1 (1-3) (fourteen-three-three beta interactant).[6][7][8]

Genes[edit]

See also[edit]

  • Sonic hedgehog, a protein that is named after a video game character.
  • Pikachurin, a retinal protein named after a Pokémon character.

References[edit]

  1. ^ Jai A. Dennison (2005-01-20). "Switching Off 'Pokemon' Gene May Block Cancer-Cell Formation". Daily News Central. Archived from the original on 2012-07-19. Retrieved 2006-06-27.
  2. ^ Maeda, Takahiro; Hobbs, Robin M.; Merghoub, Taha; Guernah, Ilhem; Zelent, Arthur; Cordon-Cardo, Carlos; Teruya-Feldstein, Julie; Pandolfi, Pier Paolo (January 2005). "Role of the proto-oncogene Pokemon in cellular transformation and ARF repression". Nature. 433 (7023): 278–285. doi:10.1038/nature03203. PMID 15662416.
  3. ^ Brendan Sinclair (2005-12-19). "Pokémon USA threatens to sue cancer researchers". GameSpot. Retrieved 2016-01-31.
  4. ^ Guo, Changcheng; Xiong, Dabo; Yang, Bin; Zhang, Haiming; Gu, Wenyu; Liu, Min; Yao, Xudong; Zheng, Junhua; Peng, Bo (October 2017). "The expression and clinical significance of ZBTB7 in transitional cell carcinoma of the bladder". Oncology Letters. 14 (4): 4857–4862. doi:10.3892/ol.2017.6814. PMC 5649710. PMID 29085492.
  5. ^ Kukita, A; Kukita, T; Ouchida, M; Maeda, H; Yatsuki, H; Kohashi, O (15 September 1999). "Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis". Blood. 94 (6): 1987–97. PMID 10477728.
  6. ^ https://www.phosphosite.org/proteinAction?id=2894&showAllSites=true
  7. ^ Komiya, Yuko; Akiyama, Hirotada; Sakumoto, Ryuji; Tashiro, Fumio (February 2014). "FBI1/Akirin2 promotes tumorigenicity and metastasis of Lewis lung carcinoma cells". Biochemical and Biophysical Research Communications. 444 (3): 382–386. doi:10.1016/j.bbrc.2014.01.064.
  8. ^ Jiang, Yuyang (23 March 2012). "Zbtb7 suppresses the expression of CDK2 and E2F4 in liver cancer cells: Implications for the role of Zbtb7 in cell cycle regulation". Molecular Medicine Reports. doi:10.3892/mmr.2012.846.